Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.40 |
| ▸ | KLK7 | P49862 | 6/20 | 0.38 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751613 | 0.85 | KCNN4 (0.39) | KCNN4KDM4EALDH1A1 | |
| SCHEMBL5749376 | 0.85 | KDM4E (0.37) | KLK7RORCKLK5PRSS1PRSS2 | |
| SCHEMBL5749959 | 0.80 | KLK7 (0.38) | KLK7RORCKLK5PRSS1PRSS2 | |
| SCHEMBL5752913 | 0.80 | MDM2 (0.43) | KCNN4TACR1 | |
| SCHEMBL7124727 | 0.76 | TACR1 (0.34) | KCNN4TACR1KLK7KLK5 | |
| SCHEMBL5752174 | 0.75 | CES2 (0.37) | RORC | |
| SCHEMBL5755094 | 0.71 | CETP (0.37) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL7118804 | 0.70 | CYP3A4 (0.39) | KDM4EALDH1A1 | |
| SCHEMBL5752580 | 0.70 | FADS1 (0.44) | RORC | |
| SCHEMBL5753504 | 0.69 | HCRTR1 (0.37) | KLK7KLK5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | KCNN4 4807/4885TACR1 2291/4885KLK7 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.